<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prolonged infusions of beta-lactam antibiotics</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prolonged infusions of beta-lactam antibiotics</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prolonged infusions of beta-lactam antibiotics</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebekah Moehring, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christina Sarubbi, PharmD, BCPS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H95812384"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics demonstrate a time-dependent effect on bacterial eradication. Prolonged infusions attain the pharmacodynamic efficacy target defined for beta-lactam antibiotics more effectively than short infusions. Thus, a prolonged infusion administration strategy may improve microbiologic and clinical cure, especially when pathogens demonstrate higher minimum inhibitory concentrations (MIC). Prolonged infusion administration strategies for intravenous beta-lactam antibiotics may include either a continuous infusion (over the entire dosing interval) or an extended infusion (over 2 to 4 hours).</p><p>This article will discuss beta-lactam pharmacodynamics, clinical evidence available for prolonged infusion strategies, the benefits and risks, and recommendations for dosing of prolonged infusion beta-lactam antibiotics.</p><p class="headingAnchor" id="H95812391"><span class="h1">PHARMACOLOGIC BACKGROUND</span><span class="headingEndMark"> — </span>Beta-lactam antibiotics kill sensitive bacteria by inactivating key enzymes involved in cell wall synthesis, termed penicillin-binding proteins. The specific beta-lactam agents have different half-lives, but all demonstrate time-dependent killing [<a href="#rid1">1</a>]. This refers to the phenomenon that the duration that the pathogen is exposed to the beta-lactam drug is the most important determinant of bacterial eradication and clinical response. This is in contrast to other antibiotic classes that exhibit concentration-dependent killing and post-antibiotic effect, such as aminoglycosides. </p><p>The duration of exposure is commonly measured as the percentage of the dosing interval that the concentration of free drug remains above the minimum inhibitory concentration (MIC) of the pathogen (%fT &gt;MIC). The maximal bactericidal effect is achieved when the free drug concentration exceeds the pathogen’s MIC by approximately fourfold for 40 to 60 percent of the dosing interval [<a href="#rid2">2</a>]. The optimal targets for %fT &gt;MIC vary depending on the specific drug  (<a class="graphic graphic_table graphicRef97448" href="/z/d/graphic/97448.html" rel="external">table 1</a>). Maximizing the duration of exposure can be accomplished in three possible ways: increasing the dose, shortening the dosing interval, or prolonging the infusion time  (<a class="graphic graphic_figure graphicRef99342" href="/z/d/graphic/99342.html" rel="external">figure 1</a>) [<a href="#rid3">3</a>]. Prolonged infusion administration strategies for intravenous beta-lactam antibiotics may include either a continuous infusion (over the entire dosing interval) or an extended infusion (over 2 to 4 hours) as opposed to traditional, intermittent infusion times (over 30 to 60 minutes). </p><p class="headingAnchor" id="H95812454"><span class="h1">RATIONALE</span><span class="headingEndMark"> — </span>Although high-quality, randomized controlled trials to support prolonged infusion beta-lactam strategies are not available, the rationale for this practice is in part based on pharmacodynamic principles and evidence of clinical benefit from observational studies and limited trials without evidence of additional toxicity. In addition, this practice is supported by a theoretical benefit of reduced emergence of drug resistance and, in some cases, measurable economic benefits.</p><p class="headingAnchor" id="H95812461"><span class="h2">Possible clinical benefit</span><span class="headingEndMark"> — </span>Clinical data suggest that prolonged (extended or continuous) infusions of beta-lactams are at least equally effective as and, in certain circumstances, such as critical illness, more effective than traditional intermittent infusions for gram-negative infections. These studies are discussed in detail elsewhere. (See <a class="local">'Clinical efficacy'</a> below.) </p><p class="headingAnchor" id="H186948969"><span class="h2">Pharmacologic advantage</span></p><p class="headingAnchor" id="H431948450"><span class="h3">Less susceptible pathogens</span><span class="headingEndMark"> — </span>Increases in pathogen resistance and rising MICs, as well as the limited number of new antibiotic agents introduced over the past 10 years, have forced clinicians to explore ways to maximize the administration of beta-lactams to achieve favorable clinical outcomes. Pharmacodynamic modeling suggests that patients with infections due to pathogens that demonstrate higher MICs but are still within the susceptible range would benefit from prolonged infusion strategies. (See <a class="local">'Pharmacologic background'</a> above.)</p><p>Predictive models of clinical response based on pharmacodynamic targets can help to identify optimal antibiotic dosing. These pharmacodynamic models allow inputs of different combinations of dose, interval, and infusion time to estimate the likelihood of attaining the targeted %fT &gt;MIC. A predictive modeling approach also allows for tailoring to certain patient population characteristics or local patterns of drug resistance, specifically the local pathogen-antibiotic MIC distribution. Several studies utilizing such models have supported prolonged infusion strategies over traditional intermittent dosing for infections due to <em>Pseudomonas aeruginosa</em> and other gram-negative pathogens with higher MICs [<a href="#rid3">3-5</a>]. Estimates from pharmacodynamic models are often the basis for alternative dosing strategies that are then evaluated clinically. (See <a class="local">'Clinical efficacy'</a> below.)</p><p class="headingAnchor" id="H431948382"><span class="h3">Patients with altered pharmacokinetics</span><span class="headingEndMark"> — </span>Critically ill or young patients, patients with cystic fibrosis, patients with malignancies, or obese patients may have creatinine clearance &gt;120 mL/min. Critical illness can also lead to variable pharmacokinetics, such as augmented drug clearance, altered volumes of distribution, abnormal fluid balance, and/or changes in protein binding [<a href="#rid6">6</a>]. Achieving adequate serum levels of antibiotics in these populations can thus be extremely challenging; higher doses and prolonged infusions may be the best pharmacologic approach in such situations.</p><p>The Defining Antibiotic Levels in Intensive Care Unit Patients (DALI) study assessed whether beta-lactam dosing in critically ill patients achieves drug concentrations associated with maximal activity and whether achievement of target concentrations correlate with clinical outcomes [<a href="#rid6">6</a>]. This prospective, multinational, pharmacokinetic point-prevalence study included 248 patients who received various beta-lactam antibiotics for treatment of an infection. The severity of illness in the study population was high (median APACHE II score 18). Thirty-three percent of infected patients received prolonged infusion dosing of beta-lactams. Patients who received prolonged infusion therapy were more likely to achieve the pharmacodynamic target (93 versus 80 percent of patients receiving intermittent infusions). Achieving an antibiotic concentration over the MIC for &gt;50 percent of the dosing interval (&gt;50%fT&gt;MIC) was associated with positive clinical outcomes for bloodstream infections but not with lung and intra-abdominal infections. Another single-center study of 52 intensive care unit (ICU) patients receiving <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> for hospital-acquired pneumonia also demonstrated improved target attainment for patients who received extended infusions compared with intermittent infusions, although it did not demonstrate a difference in clinical outcomes [<a href="#rid7">7</a>]. These studies indicate that critically ill patients have highly variable serum drug levels and that prolonged infusions do assist in attaining pharmacodynamic targets. </p><p class="headingAnchor" id="H431948801"><span class="h2">Safety</span><span class="headingEndMark"> — </span>Prolonged infusions will maintain higher serum and tissue drug concentrations than intermittent dosing, which may raise concerns about the potential for drug toxicity. However, beta-lactam drugs are well tolerated in general, and prolonged infusion strategies appear to have no more toxicity risk than intermittent dosing. Available data provide limited information about adverse events with prolonged infusion strategies. In studies that have examined adverse events, no significant differences in incidence of adverse reactions were recognized between prolonged and intermittent infusion strategies [<a href="#rid8">8-10</a>].</p><p>Renal toxicity has been observed with the combination of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> and <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, although the finding is not reliably replicated and a few studies suggest this observation may not be clinically relevant [<a href="#rid11">11-15</a>]. In one observational study of patients receiving the combination, administration of piperacillin-tazobactam as an extended infusion was not associated with higher rates of kidney injury compared with intermittent infusion, although it was associated with higher vancomycin troughs [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H95812468"><span class="h2">Reduced selection for drug resistance</span><span class="headingEndMark"> — </span>Prolonged infusions provide shorter periods of time when serum and tissue levels of the antibiotic fall lower than the MIC. Thus, there is less bacterial regrowth occurring between doses and more rapid bacterial eradication. Rapid bacterial killing, reduced organism burden, and reduced time in the presence of sub-MIC antibiotic concentrations may result in reduced opportunities for pathogens to acquire new genetic elements or de-repress chromosomal resistance genes (eg, AmpC beta-lactamases). Additionally, prolonged infusion strategies can result in lower overall exposure to the antibiotic (ie, a lower overall daily dose) without a decrease in serum concentrations (eg, <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>) [<a href="#rid17">17</a>]. Thus, on a theoretical basis, prolonged infusion strategies may provide less selective pressure than short infusions and avoid the emergence of acquired drug resistance. Evidence of this theoretical benefit is an area for future study.</p><p class="headingAnchor" id="H95812475"><span class="h2">Cost benefit</span><span class="headingEndMark"> — </span>Economic benefits of prolonged infusion strategies have been cited in several, single-center, observational studies [<a href="#rid4">4,5,17,18</a>]. As an example, manufacturer’s dosing of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> for patients with normal renal function (30-minute infusion of 3.375 to 4.5 grams every 6 hours) results in a total of 13.5 to 18 grams of drug per day. In contrast, an extended infusion strategy (4-hour infusion of 3.375 grams every 8 hours) results in a total of 10.125 grams of drug per day. The extended infusion strategy saves essentially one dose of piperacillin-tazobactam per patient day which results in drug acquisition cost savings. One study estimated that extended infusion piperacillin-tazobactam employed in a 650-bed hospital could reduce annual acquisition costs by approximately 68,750 to 137,500 US dollars per year [<a href="#rid4">4</a>]. In addition to acquisition costs, estimates of cost savings due to reduced length of stay and reduced complication rates may also be significant. In an analysis that integrated extended infusion <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> into a ventilator-associated pneumonia (VAP) pathway in three ICUs, the particular dosing regimens resulted in higher per day antibiotic acquisition costs but were estimated to reduce post-VAP hospital costs by 40,000 US dollars per patient, largely because of shorter lengths of stay [<a href="#rid19">19,20</a>]. Finally, if the prolonged infusion protocol results in longer dosing intervals (eg, every 8 hours as opposed to every 6 hours), there may be savings realized in nursing labor costs due to one less administration event per patient day.</p><p class="headingAnchor" id="H95812482"><span class="h2">Ease of administration in the outpatient setting</span><span class="headingEndMark"> — </span>Continuous infusions are easier to administer than intermittent infusions in the ambulatory setting with dedicated intravenous lines and portable, battery-powered infusion pumps. As an example, patients must access their line and change the cartridge on their pump only once in a 24-hour period, rather than every four hours with intermittent infusions. This is particularly convenient for patients who require prolonged durations of therapy delivered in the ambulatory setting (eg, outpatient parenteral antibiotic therapy for endocarditis or osteomyelitis). Continuous infusions in the outpatient setting are typically used for penicillin, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, and <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>. Many outpatient pumps can also be programmed to allow prolonged infusions of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> and <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>. </p><p class="headingAnchor" id="H95812489"><span class="h1">DRAWBACKS</span><span class="headingEndMark"> — </span>Potential drawbacks to prolonged infusion beta-lactam dosing strategies include several logistical barriers, need for continued intravenous line access, and issues of compatibility with coadministered drugs.</p><p class="headingAnchor" id="H95812495"><span class="h2">Logistical barriers</span><span class="headingEndMark"> — </span>Administration of prolonged infusions require utilization of the intravenous pump for longer periods of time, which may be problematic for patients with limited intravenous access or lower levels of nursing care. As an example, patients on a medical ward may need to ambulate to the bathroom or leave the unit for procedures, which can lead to interruptions in the infusion and impaired drug delivery. Additionally, nurses must be aware of the need to flush intravenous line tubing at the end of the infusion to allow for complete drug administration. Prolonged infusions also may result in higher intravenous catheter utilization for additional venous access. Risks of catheter-associated infections and other potential complications must be weighed with benefits of prolonged infusions for individual patients. Central catheters should not be placed for the sole reason of delivering prolonged infusions unless medical providers believe that the benefit to the individual patient outweighs the risks of central catheter placement. (See  <a class="medical medical_review" href="/z/d/html/115957.html" rel="external">"Central venous access: Device and site selection in adults", section on 'Factors influencing catheter selection'</a>.)</p><p class="headingAnchor" id="H95812502"><span class="h2">Compatibility</span><span class="headingEndMark"> — </span>Administering other intravenous medications through the same intravenous line used for a prolonged infusion of beta-lactams can be a challenge because of compatibility issues. Clinical pharmacists can assist nursing to help resolve medication scheduling and compatibility issues; however, if shifting medication administration times does not alleviate compatibility issues, reversion to intermittent infusion may be appropriate. Standard textbooks for compatibility may be used as a reference [<a href="#rid21">21,22</a>].</p><p>A common compatibility challenge occurs with <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> and <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> coadministration because compatibility is dependent on the vancomycin concentration. Of note, branded piperacillin-tazobactam (Zosyn) is formulated with EDTA, which allows for expanded compatibility with <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">amikacin</a>, and <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">Lactated Ringer</a>'s solution. The physical compatibility of vancomycin has been evaluated with both branded and generic piperacillin-tazobactam (which does not contain EDTA) in concentrations typical for prolonged infusions [<a href="#rid23">23,24</a>]. Vancomycin concentrations of less than or equal to 7 mg/mL were compatible using simulated Y-site administration with piperacillin-tazobactam 33.75 mg/mL up to 90 mg/mL. Individual institutions have different practices for compounded concentrations of vancomycin and variable piperacillin-tazobactam products. Clinicians, nurses, and pharmacists should evaluate compatibility based on available products prior to attempting to use Y-site infusions of these drugs together.</p><p class="headingAnchor" id="H95812509"><span class="h2">Stability</span><span class="headingEndMark"> — </span>If drugs are administered over a prolonged period of time, they must be stable over that time, and so not all drugs are appropriate for prolonged infusions. Stability of beta-lactams can be influenced by the type of intravenous fluid used to reconstitute the drug, the concentration of the final solution, and the storage temperature. Some beta-lactam agents, such as carbapenems, are not stable at room temperature for long durations. The product information for branded <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (Merrem) notes that meropenem prepared for infusion in normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> is stable for 1 hour at room temperature and up to 15 hours refrigerated [<a href="#rid25">25</a>]. However, studies examining stability have shown that meropenem prepared for infusion is stable for up to 12 hours at room temperature and up to 24 hours refrigerated (at concentrations up to 20 mg/mL), values that are consistent with stability documentation on generic product information [<a href="#rid26">26-29</a>]. <a class="drug drug_general" data-topicid="8737" href="/z/d/drug information/8737.html" rel="external">Ampicillin</a> and ampicillin/sulbactam are often limited to intermittent infusions because of their short half-lives; however, individual institutions may have extended stability data to allow for safe administration of continuous ampicillin and ampicillin/sulbactam, particularly for outpatient home infusion therapy [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H42557215"><span class="h1">CLINICAL EFFICACY</span><span class="headingEndMark"> — </span>Clinical data supporting prolonged infusion beta-lactam antibiotic administration resides largely in observational or non-randomized prospective studies, predominantly in adults. A clinical benefit of prolonged infusion strategies has not been definitively demonstrated in randomized controlled trials. Possible reasons that existing randomized controlled trials have not yet demonstrated benefit include small sample size and low study quality. Other limitations have been the inclusion of heterogeneous patient populations, including patients infected with highly susceptible pathogens and low severity of illness, in whom traditional dosing strategies may not need to be improved upon. Finally, there have been variable prolonged and intermittent dosing strategies used in the available studies which make compiling data in systematic reviews and meta-analyses problematic. Well-designed, adequately powered randomized controlled trials are needed to provide definitive evidence that prolonged infusion beta-lactam antibiotics provide clinical benefit.</p><p class="headingAnchor" id="H42557849"><span class="h2">Adult populations</span></p><p class="headingAnchor" id="H878664412"><span class="h3">Pooled data</span><span class="headingEndMark"> — </span>The totality of the pooled data suggests that prolonged (extended or continuous) infusions of beta-lactams are at least equally effective and, in most studies that combine data from multiple investigations, more effective than traditional intermittent infusions for gram-negative bacterial infections and in adults with sepsis [<a href="#rid8">8,9,31-35</a>]. In observational data, the greatest benefit of prolonged infusions has been primarily in critically ill patients with higher severity of illness and in patients with <em>P. aeruginosa</em> infection [<a href="#rid3">3-5,8,36</a>]. However, the data overall are limited by small samples sizes, heterogeneity of patient populations and dosing strategies, and other methodologic flaws. (See <a class="local">'Clinical efficacy'</a> above.)</p><p>In a meta-analysis of 29 studies, including 18 randomized controlled trials, comparing infusions strategies of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, cephalosporins, and carbapenems, pooled data demonstrated lower mortality (relative risk [RR] 0.66, 95% CI 0.53-0.83) with extended or continuous compared with intermittent infusions [<a href="#rid9">9</a>]. Similarly, a systematic review and meta-analysis of six studies evaluating carbapenems and/or piperacillin-tazobactam for moderate to severe gram-negative bacillary infections found a lower mortality risk with prolonged compared with intermittent infusions (RR 0.59, 95% CI 0.41-0.83) [<a href="#rid8">8</a>]. Randomized trials have had mixed results, but they demonstrate at least equivalent efficacy of continuous infusions [<a href="#rid31">31,32,37,38</a>]. In a trial from 25 intensive care units (ICUs) across Australia, New Zealand, and Hong Kong, 443 patients with severe sepsis were randomly assigned to receive continuous versus intermittent infusion of the selected beta-lactam (piperacillin-tazobactam, ticarcillin-clavulanate, or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>) [<a href="#rid37">37</a>]. There were no differences in ICU-free days at 28 days (18 versus 20 days) or clinical cure rates at 14 days (52 versus 50 percent) with continuous versus intermittent infusion. Approximately one quarter of each group was receiving renal replacement therapy, which may have attenuated the difference in drug levels achieved with the two-drug administration strategies. In contrast, in a trial of 140 patients with severe sepsis in two ICUs in Malaysia, none of whom were on renal replacement therapy, clinical cure rates at 14 days were higher among the patients randomly assigned to continuous versus intermittent therapy with piperacillin-tazobactam, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, or meropenem (56 versus 34 percent) [<a href="#rid38">38</a>]. There were no differences in ICU-free days at 28 days (20 versus 17 days). A separate meta-analysis of adults with sepsis included 22 randomized controlled trials and 1876 patients from a variety of countries. This review reported a significant association with lower all-cause mortality among patients who received prolonged beta-lactam infusions (RR 0.70, 95% CI 0.56-0.87) [<a href="#rid36">36</a>]. Trials published after 2015 have generally reported more favorable effects on mortality than earlier trials [<a href="#rid39">39</a>].</p><p>Studies of individual beta-lactam agents are discussed below. Subgroup analysis in two meta-analyses discussed above suggested that the prolonged infusions of penicillins, including <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, were associated with a mortality benefit; one of two suggested significant mortality benefit with carbapenems. Neither meta-analysis showed significantly improved mortality with prolonged infusions of cephalosporins, mostly likely due to the smaller sample [<a href="#rid9">9,36</a>]. Nevertheless, outcomes appear at least comparable between prolonged and intermittent infusions of cephalosporins. </p><p class="headingAnchor" id="H42557237"><span class="h3">Piperacillin-tazobactam</span><span class="headingEndMark"> — </span>Several, mainly observational studies have demonstrated the efficacy of extended infusions of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> for gram-negative bacterial infections and have suggested that they are associated with at least equivalent, if not superior, outcomes compared with standard, intermittent infusions. In a systematic review and meta-analysis of five randomized trials and nine observational studies, prolonged infusion of piperacillin-tazobactam was associated with a higher clinical cure rate (nine studies, OR 1.88, 95% CI 1.29-2.73) and a lower mortality rate (11 studies, OR 0.67, 95% CI 0.50-0.89) compared with intermittent infusion [<a href="#rid40">40</a>]. However, heterogeneity between comparison groups and limitations inherent in observational studies decrease confidence in the findings of many of these studies. </p><p>Some observational studies suggested lower mortality with extended infusion of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> [<a href="#rid4">4,41,42</a>]. However in some cases, baseline differences compared with the intermittent infusion cohorts suggested that confounding variables could have affected the observation [<a href="#rid4">4,41,42</a>]. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>In a single center, retrospective study of critically ill adult patients with <em>P. aeruginosa</em> infection, 102 patients who were treated with an extended infusion of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> (3.375 grams infused over 4 hours every 8 hours) were compared to a historical group of 92 patients who received intermittent infusions (3.375 grams infused over 30 minutes every 6 hours) [<a href="#rid4">4</a>]. Among patients with a greater severity of illness (APACHE II scores ≥17) at presentation, the extended infusion strategy was associated with a lower 14-day mortality (12 versus 32 percent with intermittent infusions) and shorter length of stay (21 versus 38 days). Extended infusion was not associated with any difference in outcomes for patients with lesser severity of illness. Of note, the comparator, intermittent infusion group was given a lower dose than typically recommended for treatment of <em>P. aeruginosa</em> infections.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Retrospective Cohort of Extended-Infusion <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">Piperacillin-Tazobactam</a> (RECEIPT) multicenter study of adult patients with gram-negative bacterial infections, 186 patients receiving extended infusion piperacillin-tazobactam were compared with 173 patients receiving intermittent infusions of comparator beta-lactam antibiotics (ie, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, doripenem, or piperacillin-tazobactam) [<a href="#rid41">41</a>]. Multivariate analysis demonstrated reduced odds of mortality in the extended infusion group. However, there were important baseline differences between the groups. Although severity of illness scores, hospital and ICU lengths of stay, and antibiotic durations were comparable, fewer patients in the extended-infusion group were infected with <em>P. aeruginosa, </em>received concomitant intravenous aminoglycosides, or had positive respiratory cultures.</p><p></p><p>In contrast, some observational studies that have not suggested a mortality benefit may have evaluated patient populations that would be less affected by optimizing antibiotic levels [<a href="#rid43">43-45</a>]. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>A cohort study of 129 patients with gram-negative bacillary infections suggested equivalent outcomes but failed to demonstrate improved clinical outcomes with extended infusion <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> compared with intermittent infusion (4.5 grams every 6 hour dosing) [<a href="#rid43">43</a>]. Patients in this study were infected with pathogens with low MICs (ie, more susceptible pathogens) and low severity of illness scores. Only a minority had <em>P. aeruginosa</em> infections. These factors, along with the small study size, may explain its failure to demonstrate a beneficial effect [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of 553 ICU patients who received <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> for ≥72 hours reported that extended infusion (4.5 gram loading dose followed by 3.375 grams every eight-hour dosing) was associated with a comparable mortality rate but a shorter length of hospital stay compared with intermittent infusion [<a href="#rid45">45</a>]. However, <em>P. aeruginosa</em> was isolated from approximately 5 percent of patients overall, and the majority of study patients (&gt;65 percent) did not have microbiologically confirmed infections.</p><p></p><p>Administration of <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> as a continuous infusion over 24 hours also has similar pharmacologic and clinical outcomes to intermittent infusion comparators as demonstrated by small, single center, randomized studies [<a href="#rid17">17,46,47</a>]. As an example, an open-label, randomized study in a US community hospital evaluated 262 patients with complicated intra-abdominal infections randomized to receive continuous infusion piperacillin-tazobactam (13.5 grams over 24 hours) or intermittent infusion (3.375 grams over 30 minutes every 6 hours) [<a href="#rid46">46</a>]. There were no differences in clinical and microbiologic cure between the two groups. </p><p class="headingAnchor" id="H42557378"><span class="h3">Carbapenems</span><span class="headingEndMark"> — </span>Extended or continuous infusions of carbapenems are associated with similar mortality rates compared with traditional intermittent infusions, but may result in other benefits, as suggested by limited data [<a href="#rid48">48</a>]. In a single-center randomized, open-label trial in 240 adult ICU patients, administration of <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> by continuous infusion resulted in similar mortality (16 percent) and clinical cure rates that were not statistically different (83 versus 75 percent) compared with intermittent infusion, but microbiologic success rates (90 versus 78 percent) were higher, and ICU stays and duration of therapy were shorter with continuous infusion [<a href="#rid49">49</a>].</p><p>Observational data suggest generally similar findings [<a href="#rid8">8,50-55</a>]. As an example, a retrospective study of patients with hematologic malignancies and febrile neutropenia compared outcomes between 76 patients who received extended infusion <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (1 gram over 4 hours every 8 hours) with 88 who received conventional intermittent infusion meropenem (1 gram over 30 minutes every 8 hours) [<a href="#rid56">56</a>]. Extended infusion was associated with greater day 5 treatment success (defined as fever resolution, improvement in infectious symptoms, absence of bacteremia, and no need for additional antibiotics), but there were no differences in length of stay and 100-day mortality between the two infusion strategies. </p><p>A multicenter, double-blind, randomized study performed in 2022 compared outcomes of 607 ICU patients with sepsis (most of whom had septic shock and required mechanical ventilation) who received either continuous or intermittent infusion <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> [<a href="#rid48">48</a>]. Continuous infusion was not associated with a difference in the composite outcome of all-cause mortality and the emergence of drug-resistant bacteria at day 28. Antibiotic-free days, days free from the ICU, and 90-day mortality were also not different between groups. Subgroup analyses performed for hypothesis generation also did not detect significant effects among patients with pathogens with a high MIC to meropenem. The study population was from Russia, Croatia, Italy, and Kazakhstan and had high baseline rates of carbapenem resistance (35 percent in continuous infusion group versus 30 percent in the intermittent infusion group). The emergence of drug resistance was common in both groups (24 percent continuous versus 25 percent intermittent). Thus, the choice of meropenem was not optimal for several participants, and findings may not be generalizable to populations with lower baseline resistance. Most participants had respiratory infections; only 10 percent had confirmed bacteremia. Although large, the trial may have been underpowered to detect a benefit in patients with invasive infection (eg, gram-negative bacteremia). Importantly, this large trial did not detect differences in rates of toxicity or harm. Overall, this study was unable to prove that continuous infusion of meropenem was more effective than intermittent infusion but was limited in applicability. Although not statistically significant, the overall direction of effect was in favor of continuous infusion. Therefore, addition of this trial to prior pooled data may or may not alter the results of future meta-analyses studying the effects of prolonged infusions of beta lactams. In the meantime, we continue to favor extended infusion meropenem given its lack of harm and possibility of benefit.</p><p class="headingAnchor" id="H42557511"><span class="h3">Cephalosporins</span><span class="headingEndMark"> — </span>Extended continuous infusions of cephalosporins are associated with similar outcomes as traditional intermittent infusions. A meta-analysis of 10 randomized trials and 1 non-randomized trial did not demonstrate a difference in mortality or clinical cure when comparing third- and fourth-generation cephalosporins administered via extended or continuous infusion versus intermittent infusion [<a href="#rid57">57</a>]. The total daily dose of antibiotics in the extended or continuous infusion arms were substantially lower than in the short infusion groups in many of the included studies, yet clinical outcomes were not different. </p><p>A subsequent retrospective study compared outcomes in patients with positive respiratory or blood cultures with a gram-negative organism before and after a hospital-wide change from intermittent to extended infusion of <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> (2 grams over 30 min to 2 grams over 4 hours, each every 8 to 24 hours) [<a href="#rid5">5</a>]. Overall mortality, lengths of stay, and hospital costs were similar between the groups. However, in a subgroup analysis of 87 patients with infections due to <em>P. aeruginosa</em>, mortality was lower among patients who received prolonged infusion cefepime (3 versus 20 percent with intermittent infusion) as was ICU length of stay (8 versus 19 days).</p><p>Intraoperative continuous infusion <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> has been proposed to maintain optimal concentrations during surgeries requiring the use of cardiopulmonary bypass. A retrospective cohort study compared outcomes between 284 patients who received cefazolin administered as a weight-based intermittent dose every two hours and 232 patients who received cefazolin administered as a 1 gram per hour continuous infusion during cardiac surgery [<a href="#rid58">58</a>]. All patients received a weight-based loading dose prior to incision. Continuous infusion was associated with a reduction in superficial surgical site infections (0.4 percent versus 2.8 percent in the intermittent infusion group); however, the study was underpowered to detect a significant difference in overall SSIs.</p><p class="headingAnchor" id="H4150299917"><span class="h3">Novel beta-lactams (cefiderocol, advanced beta-lactam combinations)</span><span class="headingEndMark"> — </span>Most of the advanced beta-lactams that target multidrug-resistant gram-negative pathogens were evaluated with and are administered using prolonged-infusion strategies. As examples, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> and <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a> are administered with extended infusions over three hours [<a href="#rid59">59,60</a>]. In contrast, the manufacturer specifies intermittent dosing with 30-minute infusion times for <a class="drug drug_general" data-topicid="121885" href="/z/d/drug information/121885.html" rel="external">imipenem-cilastatin-relebactam</a> [<a href="#rid61">61</a>]. This difference is likely related, in part, to imipenem-cilastatin-relebactam stability limitations of two hours at room temperature; available pharmacokinetic models also suggest that relebactam activity best followed a concentration-time curve (AUC/MIC) and thus would not be affected by infusion duration [<a href="#rid62">62</a>].</p><p>Pharmacodynamic data support the use of prolonged infusion <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> [<a href="#rid63">63,64</a>], and one small observational study of patients with <em>P. aeruginosa</em> infections suggested that extended infusion of ceftolozane-tazobactam was associated with a lower likelihood of treatment-emergent resistance to ceftolozane-tazobactam [<a href="#rid65">65</a>]. The manufacturer recommends that <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a> be infused over two hours; population pharmacokinetic models show that two-hour infusions have a higher likelihood of target attainment than a 30-minute intermittent infusion [<a href="#rid66">66,67</a>]. However, observational data on patients with <em>Klebsiella pneumoniae</em> carbapenemase (KPC)-producing <em>K. pneumoniae</em> infections suggest that a three-hour infusion is associated with a mortality benefit [<a href="#rid68">68</a>]. As a result, some institutions use a three- rather than two-hour infusion of ceftazidime-avibactam. </p><p class="headingAnchor" id="H42557560"><span class="h3">Other beta-lactams</span><span class="headingEndMark"> — </span>The efficacy of continuous versus intermittent infusion <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> has also been assessed in a single-center, retrospective cohort study [<a href="#rid69">69</a>]. Patients with methicillin-susceptible <em>Staphylococcus aureus</em> endocarditis received either intermittent infusion oxacillin (2 grams over 30 minutes every 4 hours; n = 29) or continuous infusion oxacillin (12 grams continuously over 24 hours; n = 78). The primary outcome was microbiologic cure at 30 days, which was defined as no positive cultures within 30 days of the end of treatment. Clinical cure was not evaluated. Continuous infusion was associated with greater microbiologic cure, (94 versus 79 percent with intermittent infusion), but 30-day mortality rates, lengths of stay, time to defervescence, and clearance of bacteremia were not different.</p><p>Continuous infusion administration of <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> and <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, a monobactam with similar pharmacokinetic and microbiologic activity to ceftazidime, has been evaluated in small series using various total daily doses, mainly in patients with cystic fibrosis [<a href="#rid70">70-75</a>]. We do not administer ceftazidime as extended infusion, as pharmacokinetic/pharmacodynamics studies to inform the optimal dosing and schedule are limited. However, some institutions may employ extended infusion administration of ceftazidime using institution-specific dosing protocols. </p><p>We administer <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> over three hours when used in combination therapy with <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>/avibactam for the treatment of antimicrobial resistant infections, such as for <em>Stenotrophomonas</em> or metallo-beta-lactamase producing carbapenem-resistant Enterobacterales [<a href="#rid76">76</a>]. Similarly, the preferred treatment of carbapenem-resistant <em>Acinetobacter</em> infections includes high dose <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a> with a prolonged infusion strategy [<a href="#rid76">76</a>]. We recommend consultation with an infectious diseases specialist for treatment of multidrug-resistant pathogens.</p><p class="headingAnchor" id="H42557688"><span class="h2">Pediatric populations</span><span class="headingEndMark"> — </span>Prolonged infusion beta lactam studies in children are very limited but suggest at least similar, if not improved, clinical outcomes compared with traditional dosing. </p><p>A 2012 systematic review located one small randomized controlled clinical trial, five pharmacokinetic studies, two pharmacodynamic studies using Monte Carlo simulation, one case series, and seven case reports [<a href="#rid77">77</a>]. Studied agents included <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, and various penicillins, and no definitive conclusions could be made. The single randomized controlled trial included in the review evaluated continuous infusion ceftazidime in 14 children with cystic fibrosis and <em>P. aeruginosa</em> lung infection and demonstrated similar clinical outcomes to intermittent infusions [<a href="#rid78">78</a>]. In contrast, in a subsequent single-center randomized trial of 102 neonates with late-onset sepsis due to gram-negative bacteremia or meningitis in Egypt, extended infusion of meropenem (over four hours) resulted in lower neonatal mortality rates (14 versus 31 percent) compared with conventional dosing (over 30 minutes) [<a href="#rid79">79</a>]. Seven-day bacterial eradication and clinical improvement rates as well as duration of respiratory support were also more favorable with extended-infusion dosing. This survival benefit has not been observed in other studies. A retrospective chart analysis of children who received extended versus intermittent infusion <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, or meropenem found that bone marrow transplant and critical care patients who received extended infusions showed fewer readmissions and lower all-cause mortality [<a href="#rid80">80</a>]</p><p>Descriptive implementation studies of hospital-wide protocols have demonstrated that extended infusion strategies are feasible in pediatric populations; however these studies did not provide analysis of clinical outcomes [<a href="#rid80">80-82</a>]. </p><p class="headingAnchor" id="H95812523"><span class="h1">POTENTIAL INDICATIONS</span><span class="headingEndMark"> — </span>Indications for the use of prolonged infusion strategies with beta-lactams are not established for most routine scenarios. However, prolonged infusion approaches are included specifically in guidance for treatment of resistant gram-negative pathogens [<a href="#rid76">76</a>]. Pharmacodynamic modeling suggests that the situations in which prolonged infusion strategies would offer a clinical benefit over traditional intermittent strategies are infections with organisms that have a high, but still susceptible-range MIC to the chosen beta-lactam. Limited data from clinical studies suggest that patients with a high severity of illness or with <em>P. aeruginosa</em> infection are more likely to benefit from prolonged infusion strategies. (See <a class="local">'Pharmacologic advantage'</a> above and <a class="local">'Clinical efficacy'</a> above.) </p><p>Thus, populations with the most potential clinical benefit from prolonged infusion strategies include patients with an elevated risk of drug-resistant pathogens and/or patients with severe infections who may have altered pharmacokinetics. These include patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Structural lung disease (including cystic fibrosis)</p><p class="bulletIndent1"><span class="glyph">●</span>Frequent healthcare exposures</p><p class="bulletIndent1"><span class="glyph">●</span>Prior repeated antibiotic exposures</p><p class="bulletIndent1"><span class="glyph">●</span>Critical illness with severe infection (including central nervous system infections [<a href="#rid83">83,84</a>],<em> </em>necrotizing fasciitis, neutropenic fever [<a href="#rid34">34,85,86</a>], and burns)</p><p class="bulletIndent1"><span class="glyph">●</span>Infections due to pathogens with high intrinsic resistance and predilection for developing acquired resistance during therapy (eg, <em>P. aeruginosa</em>, <em>Burkholderia cepacia</em>, <em>Acinetobacter baumannii</em>)</p><p class="bulletIndent1"><span class="glyph">●</span>Infections that require advanced beta-lactam agents that target multidrug-resistant pathogens (eg, <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">ampicillin-sulbactam</a>, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a>, <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a>, <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a>, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>) [<a href="#rid76">76</a>]</p><p></p><p>When <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, or <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> is chosen for treatment in such patients, we suggest a prolonged infusion dosing strategy. <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a>, and <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a> are typically administered as prolonged infusions. In particular, we favor prolonged infusions for critically ill patients with gram-negative bacterial infections, for patients with infections due to gram-negative bacteria that have elevated but susceptible minimum inhibitory concentrations (MIC) to the chosen agent, and for patients with multidrug-resistant gram-negative bacterial infections. Our practices match those of expert guidelines for treatment of multidrug-resistant gram-negative bacterial infections [<a href="#rid76">76</a>].</p><p>In some cases, logistical issues can outweigh the potential benefit of prolonged infusions. Thus, the decision to use a prolonged infusion dosing strategy in individual patients must also take into account whether intravenous access is limited (since a prolonged infusion would utilize an intravenous catheter for a longer time), whether other administered drugs are compatible for co-infusion with the antibiotic, and whether nursing staff can accommodate the potential extra care with a prolonged infusion (see <a class="local">'Drawbacks'</a> above). Clinicians are encouraged to engage local pharmacy experts and nursing staff to discuss feasibility and compatibility challenges for individual patients. Consultation with an expert in infectious diseases is also valuable when dealing with infections involving pathogens with limited antibiotic susceptibility.</p><p>Some hospitals have implemented policies to encourage the use of prolonged infusions even in patients with low severity of illness, a policy that can have an economic benefit. (See <a class="local">'Institutional implementation'</a> below.)</p><p class="headingAnchor" id="H4232627081"><span class="h1">ADMINISTRATION</span></p><p class="headingAnchor" id="H42557902"><span class="h2">Dosing</span><span class="headingEndMark"> — </span>Optimal dosing for prolonged infusion of beta-lactams has not been well established. Our recommendations on dosing for adult patients with adequate intravenous access  (<a class="graphic graphic_table graphicRef99434" href="/z/d/graphic/99434.html" rel="external">table 2</a>) are based on data from pharmacodynamic models [<a href="#rid1">1,5,63,67,69,87-90</a>]. However, dosing should be reviewed on a case-by-case basis, as such models are based on minimum inhibitory concentration (MIC) distribution assumptions that may not match local patterns. Beta-lactams are also dose-adjusted for renal impairment.</p><p>We limit use of prolonged infusion carbapenems to three-hour infusions and to the indications discussed above due to impaired stability of <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a> and <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> at room temperature; although data are emerging to suggest that stability may be adequate, it is uncertain whether infusions longer than three hours (eg, continuous infusions) offer any clinical or practical benefit. (See <a class="local">'Potential indications'</a> above.)</p><p>Penicillins (eg, <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>) that are stable at room temperature for greater than 24 hours can be used in the outpatient setting with continuous infusion pumps. These agents are dosed by summing the total daily dose and then extending the infusion over 24 hours. As an example, nafcillin dosed intermittently at 2 grams every 4 hours with 30-minute infusions would be continuously infused as 12 grams over 24 hours.</p><p class="headingAnchor" id="H1135181106"><span class="h2">Loading doses</span><span class="headingEndMark"> — </span>Loading doses are sometimes used for patients with sepsis to try to achieve therapeutic drug levels more rapidly and are recommended in this setting by the Surviving Sepsis Campaign Guidelines [<a href="#rid91">91</a>]. For <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, a 3.375 g to 4.5 g loading dose can be given over 0.5 hours. This approach may be particularly useful in institutions with higher <em>P. aeruginosa </em>MIC distributions to achieve faster target attainment. The optimal time to start the subsequent extended infusion is 4 hours later in patients with CrCl &gt;20 mL/min and 8 hours later in patients with CrCl &lt;20 mL/min. While data from various studies are mixed, a systematic review and meta-regression found increased clinical cure rates in patients who received loading doses [<a href="#rid88">88,92,93</a>].</p><p class="headingAnchor" id="H37016916"><span class="h2">Drug monitoring</span><span class="headingEndMark"> — </span>We do not routinely monitor drug levels in patients receiving prolonged beta-lactam infusions. Although therapeutic drug monitoring of beta-lactams may help better achieve target drug levels in patients receiving nontraditional prolonged dosing regimens to maximize clinical efficacy, the clinical utility of these tests in this setting has not been proven [<a href="#rid94">94</a>]. Turnaround time and cost are further considerations in assessing their value. </p><p class="headingAnchor" id="H186949303"><span class="h1">INSTITUTIONAL IMPLEMENTATION</span><span class="headingEndMark"> — </span>The 2016 Infectious Diseases Society of America (IDSA) guidelines for implementation of antimicrobial stewardship programs make a weak recommendation for use of alternative dosing strategies for broad-spectrum beta-lactams among hospitalized patients in order to decrease costs [<a href="#rid95">95</a>]. Institutional policies that promote prolonged infusion strategies for empiric use of beta-lactams have been successfully employed at several medical centers [<a href="#rid1">1,3,5,96</a>]. </p><p>Local hospital- or ICU-specific pathogen susceptibility (and minimum inhibitory concentration [MIC] distributions) should be considered when determining whether to incorporate prolonged infusion strategies into institution-specific guidelines for clinical syndromes and empiric therapies [<a href="#rid3">3</a>]. The clinical microbiology laboratory plays an important role in both reporting pathogen MIC values in a meaningful way for clinicians to interpret them, as well as monitoring for shifts in institutional MIC distributions. Laboratories should assist clinicians in identifying high-risk scenarios of elevated, but susceptible, MIC pathogens to target for optimized dosing strategies [<a href="#rid94">94</a>]. (See  <a class="medical medical_review" href="/z/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Interpretation of results'</a>.)</p><p>Acute care hospitals or specific hospital units that frequently encounter drug-resistant gram-negative pathogens may be more apt to adopt prolonged infusion strategies as an antimicrobial stewardship initiative. Extended infusion <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> is the beta-lactam most commonly chosen for institutional policies due to high utilization of this drug and the acquisition cost savings associated with the switch to extended infusion. </p><p>Pharmacodynamic studies employing Monte Carlo simulation tailored to institutional MIC distributions allows for selection of the dosing strategies most likely to benefit the selected patient populations and is the preferred approach when planning an institutional dosing strategy [<a href="#rid3">3</a>]. If the approach is only to target certain hospital units, dosing can be challenging when transfers between units require adjustment of dosing strategies for a single patient. </p><p>Furthermore, careful weighing of the risks outlined above to the estimated benefits and plans to address the logistical implementation challenges must be addressed at the institutional level [<a href="#rid96">96</a>]. </p><p>Several examples in the medical literature support the feasibility of facility- or unit-wide policies. Single-center, quasi-experimental studies of institutional protocols for extended infusion <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a> have demonstrated similar clinical outcomes as with intermittent infusions, reductions in drug acquisition costs (13 to 29 percent), and reductions in total amount of drug received [<a href="#rid97">97-99</a>]. One study in two intensive care units (ICUs) in a community hospital also observed reduced lengths of ICU and overall hospital stay [<a href="#rid97">97</a>]. </p><p class="headingAnchor" id="H95812573"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale</strong> – Beta-lactam antibiotics demonstrate a time-dependent effect on bacterial eradication. Infusing the antibiotic over a prolonged period of time (eg, over four hours at each dose or even continuously) can more effectively attain pharmacodynamic target levels compared with short, intermittent infusions. This pharmacologic advantage offers a potential clinical benefit to patients with altered pharmacokinetics or with infections due to less susceptible pathogens. (See <a class="local">'Pharmacologic background'</a> above and <a class="local">'Pharmacologic advantage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical efficacy</strong> – Clinical data suggest that prolonged infusions of beta-lactams are at least equally effective as traditional intermittent infusions for gram-negative bacterial infections. Observational studies and meta-analyses of randomized trials suggest that prolonged infusions in critically ill patients are associated with a mortality benefit compared with intermittent infusions. (See <a class="local">'Clinical efficacy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other benefits</strong> – Additional potential benefits of prolonged infusion strategies include cost savings, ease of administration in ambulatory settings, and a theoretical reduction in risk of acquired drug resistance. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drawbacks</strong> – Potential drawbacks to prolonged infusion beta-lactam dosing strategies include several logistical barriers, such as need for intravenous line access, drug stability at room temperature, and compatibility with coadministered intravenous drugs. (See <a class="local">'Drawbacks'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – Indications for the use of prolonged infusion strategies with beta-lactams are not well established for most routine scenarios, but prolonged infusions are specifically recommended for treatment of drug-resistant pathogens. The pharmacologic and clinical data indicate that patients who have an elevated risk of drug-resistant pathogens or who are critically ill in the setting of a severe infection are most likely to benefit. When <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">piperacillin-tazobactam</a>, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a>, <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">imipenem</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, or <a class="drug drug_general" data-topicid="98763" href="/z/d/drug information/98763.html" rel="external">ceftolozane-tazobactam</a> is chosen for treatment in such patients, we suggest a prolonged infusion dosing strategy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="100152" href="/z/d/drug information/100152.html" rel="external">Ceftazidime-avibactam</a>, <a class="drug drug_general" data-topicid="114672" href="/z/d/drug information/114672.html" rel="external">meropenem-vaborbactam</a>, and <a class="drug drug_general" data-topicid="126182" href="/z/d/drug information/126182.html" rel="external">cefiderocol</a> are typically administered as prolonged infusions. In particular, we favor prolonged infusion dosing for critically ill patients with gram-negative bacterial infections, for patients with infections due to gram-negative bacteria that have elevated but susceptible minimum inhibitory concentrations (MIC) to the chosen agent, and for patients with multidrug-resistant gram-negative bacterial infections. The decision to use this dosing strategy should also take into account logistical issues such as staffing or intravenous access availability. (See <a class="local">'Potential indications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing</strong> – Optimal dosing for prolonged infusion of beta-lactams has not been established. Our preferred dosing for adult patients with adequate intravenous access  (<a class="graphic graphic_table graphicRef99434" href="/z/d/graphic/99434.html" rel="external">table 2</a>) is based on data from pharmacodynamic models. Beta-lactams are dose-adjusted for renal impairment. (See <a class="local">'Dosing'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lodise TP, Lomaestro BM, Drusano GL, Society of Infectious Diseases Pharmacists. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2006; 26:1320.</a></li><li class="breakAll">Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998; 26:1; quiz 1-2.</li><li><a class="nounderline abstract_t">MacVane SH, Kuti JL, Nicolau DP. Prolonging β-lactam infusion: a review of the rationale and evidence, and guidance for implementation. Int J Antimicrob Agents 2014; 43:105.</a></li><li><a class="nounderline abstract_t">Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44:357.</a></li><li><a class="nounderline abstract_t">Bauer KA, West JE, O'Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013; 57:2907.</a></li><li><a class="nounderline abstract_t">Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 2014; 58:1072.</a></li><li><a class="nounderline abstract_t">Bao H, Lv Y, Wang D, et al. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial. Eur J Clin Microbiol Infect Dis 2017; 36:459.</a></li><li><a class="nounderline abstract_t">Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 2013; 56:272.</a></li><li><a class="nounderline abstract_t">Teo J, Liew Y, Lee W, Kwa AL. Prolonged infusion versus intermittent boluses of β-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents 2014; 43:403.</a></li><li><a class="nounderline abstract_t">Cotner SE, Rutter WC, Burgess DR, et al. Influence of β-Lactam Infusion Strategy on Acute Kidney Injury. Antimicrob Agents Chemother 2017; 61.</a></li><li><a class="nounderline abstract_t">Watkins RR, Deresinski S. Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do? Clin Infect Dis 2017; 65:2137.</a></li><li><a class="nounderline abstract_t">Bellos I, Karageorgiou V, Pergialiotis V, Perrea DN. Acute kidney injury following the concurrent administration of antipseudomonal β-lactams and vancomycin: a network meta-analysis. Clin Microbiol Infect 2020; 26:696.</a></li><li><a class="nounderline abstract_t">Blair M, Côté JM, Cotter A, et al. Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A Comprehensive Review. Am J Nephrol 2021; 52:85.</a></li><li><a class="nounderline abstract_t">Miano TA, Hennessy S, Yang W, et al. Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Med 2022; 48:1144.</a></li><li><a class="nounderline abstract_t">Côté JM, Desjardins M, Cailhier JF, et al. Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients. PLoS One 2022; 17:e0264281.</a></li><li><a class="nounderline abstract_t">Mousavi M, Zapolskaya T, Scipione MR, et al. Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion. Pharmacotherapy 2017; 37:379.</a></li><li><a class="nounderline abstract_t">Buck C, Bertram N, Ackermann T, et al. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 2005; 25:62.</a></li><li><a class="nounderline abstract_t">Florea NR, Kotapati S, Kuti JL, et al. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study. Am J Health Syst Pharm 2003; 60:2321.</a></li><li><a class="nounderline abstract_t">Nicasio AM, Eagye KJ, Nicolau DP, et al. Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010; 25:69.</a></li><li><a class="nounderline abstract_t">Nicasio AM, Eagye KJ, Kuti EL, et al. Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010; 30:453.</a></li><li class="breakAll">Trissel L. Handbook on Injectable Drugs. 17th ed. Bethesda, Maryland: American Society of Health-System Pharmacists; 2013.</li><li class="breakAll">Intravenous Medications. 30th ed. St. Louis: Elsevier Mosby; 2014.</li><li><a class="nounderline abstract_t">Leung E, Venkatesan N, Ly SC, Scheetz MH. Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions. Am J Health Syst Pharm 2013; 70:1163.</a></li><li><a class="nounderline abstract_t">O'Donnell JN, Venkatesan N, Manek M, et al. Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations. Am J Health Syst Pharm 2016; 73:241.</a></li><li class="breakAll">Merrem (meropenem) [prescribing information]. Wilmington, DE: AztraZeneca; 2013.</li><li><a class="nounderline abstract_t">Patel PR, Cook SE. Stability of meropenem in intravenous solutions. Am J Health Syst Pharm 1997; 54:412.</a></li><li class="breakAll">Meropenem for injection. [prescribing information]. Lake Forest, IL.: Hospira, Inc.; 2013.</li><li><a class="nounderline abstract_t">Venugopalan V, Manigaba K, Borgert SJ, et al. Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion. Microbiol Insights 2018; 11:1178636118804549.</a></li><li class="breakAll">Meropenem. In: ASHP’s Extended Stability for Parenteral Drugs, 6th, Caryn Dellamorte Bing and Anna Nowobilski-Vasilios (Ed), 2017.</li><li><a class="nounderline abstract_t">Williams DN, Raymond JL. Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues. Clin Pharmacokinet 1998; 35:65.</a></li><li><a class="nounderline abstract_t">Arnold HM, Hollands JM, Skrupky LP, et al. Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study. Ann Pharmacother 2013; 47:170.</a></li><li><a class="nounderline abstract_t">Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56:236.</a></li><li><a class="nounderline abstract_t">Shiu J, Wang E, Tejani AM, Wasdell M. Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections. Cochrane Database Syst Rev 2013; :CD008481.</a></li><li><a class="nounderline abstract_t">Ram R, Halavy Y, Amit O, et al. Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial. Clin Infect Dis 2018; 67:1153.</a></li><li><a class="nounderline abstract_t">Tran NN, Mynatt RP, Kaye KS, et al. Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia. Open Forum Infect Dis 2023; 10:ofad170.</a></li><li><a class="nounderline abstract_t">Vardakas KZ, Voulgaris GL, Maliaros A, et al. Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials. Lancet Infect Dis 2018; 18:108.</a></li><li><a class="nounderline abstract_t">Dulhunty JM, Roberts JA, Davis JS, et al. A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. Am J Respir Crit Care Med 2015; 192:1298.</a></li><li><a class="nounderline abstract_t">Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med 2016; 42:1535.</a></li><li><a class="nounderline abstract_t">Kondo Y, Ota K, Imura H, et al. Prolonged versus intermittent β-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of randomized trials. J Intensive Care 2020; 8:77.</a></li><li><a class="nounderline abstract_t">Yang H, Zhang C, Zhou Q, et al. Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis. PLoS One 2015; 10:e0116769.</a></li><li><a class="nounderline abstract_t">Yost RJ, Cappelletty DM, RECEIPT Study group. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study. Pharmacotherapy 2011; 31:767.</a></li><li><a class="nounderline abstract_t">Bartoletti M, Giannella M, Lewis RE, et al. Extended Infusion of β-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study. Clin Infect Dis 2019; 69:1731.</a></li><li><a class="nounderline abstract_t">Patel GW, Patel N, Lat A, et al. Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections. Diagn Microbiol Infect Dis 2009; 64:236.</a></li><li><a class="nounderline abstract_t">Kaufman SE, Donnell RW, Hickey WS. Rationale and evidence for extended infusion of piperacillin-tazobactam. Am J Health Syst Pharm 2011; 68:1521.</a></li><li><a class="nounderline abstract_t">Chan JD, Dellit TH, Lynch JB. Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units. J Intensive Care Med 2018; 33:134.</a></li><li><a class="nounderline abstract_t">Lau WK, Mercer D, Itani KM, et al. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006; 50:3556.</a></li><li><a class="nounderline abstract_t">Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22:471.</a></li><li><a class="nounderline abstract_t">Monti G, Bradic N, Marzaroli M, et al. Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial. JAMA 2023; 330:141.</a></li><li><a class="nounderline abstract_t">Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care 2012; 16:R113.</a></li><li><a class="nounderline abstract_t">Okimoto N, Ishiga M, Nanba F, et al. [Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly]. Nihon Kokyuki Gakkai Zasshi 2009; 47:553.</a></li><li><a class="nounderline abstract_t">Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007; 51:3304.</a></li><li><a class="nounderline abstract_t">Itabashi S. [Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia]. Jpn J Antibiot 2007; 60:161.</a></li><li><a class="nounderline abstract_t">Wang D. Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii. Int J Antimicrob Agents 2009; 33:290.</a></li><li><a class="nounderline abstract_t">Lorente L, Lorenzo L, Martín MM, et al. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40:219.</a></li><li><a class="nounderline abstract_t">Hsaiky L, Murray KP, Kokoska L, et al. Standard versus prolonged doripenem infusion for treatment of gram-negative infections. Ann Pharmacother 2013; 47:999.</a></li><li><a class="nounderline abstract_t">Fehér C, Rovira M, Soriano A, et al. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother 2014; 69:2556.</a></li><li><a class="nounderline abstract_t">Korbila IP, Tansarli GS, Karageorgopoulos DE, et al. Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis. Expert Rev Anti Infect Ther 2013; 11:585.</a></li><li><a class="nounderline abstract_t">Shoulders BR, Crow JR, Davis SL, et al. Impact of Intraoperative Continuous-Infusion Versus Intermittent Dosing of Cefazolin Therapy on the Incidence of Surgical Site Infections After Coronary Artery Bypass Grafting. Pharmacotherapy 2016; 36:166.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis 2021; 21:213.</a></li><li class="breakAll">Cefiderocol. US Food and Drug Administration (FDA) approved product information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209445s002lbl.pdf (Accessed on September 29, 2020).</li><li class="breakAll">Imipenem, cilastatin, and relebactam. US Food and Drug Administration approved product information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212819s000lbl.pdf (Accessed on June 18, 2021).</li><li><a class="nounderline abstract_t">Wu J, Racine F, Wismer MK, et al. Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model. Antimicrob Agents Chemother 2018; 62.</a></li><li class="breakAll">Hershberger E, Moukasassi MS, Steenbergen J, et al. CXA-101/Tazobactam (CXA/TAZ) probability of target attainment using population pharmacokinetic analysis. Presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases, Milan Italy May 2011.</li><li><a class="nounderline abstract_t">Natesan S, Pai MP, Lodise TP. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. J Antimicrob Chemother 2017; 72:2813.</a></li><li><a class="nounderline abstract_t">Tamma PD, Beisken S, Bergman Y, et al. Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance. Clin Infect Dis 2021; 73:e4599.</a></li><li><a class="nounderline abstract_t">Bremmer DN, Nicolau DP, Burcham P, et al. Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy. Pharmacotherapy 2016; 36:e30.</a></li><li class="breakAll">Avycaz [Prescribing Information]. Cincinnati, OH: Forrest Pharmaceuticals, Inc.; 2015.</li><li><a class="nounderline abstract_t">Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study. Clin Infect Dis 2021; 73:1664.</a></li><li><a class="nounderline abstract_t">Hughes DW, Frei CR, Maxwell PR, et al. Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53:2014.</a></li><li><a class="nounderline abstract_t">Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17:497.</a></li><li><a class="nounderline abstract_t">Lorente L, Jiménez A, Palmero S, et al. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review. Clin Ther 2007; 29:2433.</a></li><li><a class="nounderline abstract_t">Riethmueller J, Junge S, Schroeter TW, et al. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009; 37:418.</a></li><li><a class="nounderline abstract_t">Hubert D, Le Roux E, Lavrut T, et al. Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis. Antimicrob Agents Chemother 2009; 53:3650.</a></li><li><a class="nounderline abstract_t">Burgess DS, Summers KK, Hardin TC. Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion. Clin Ther 1999; 21:1882.</a></li><li><a class="nounderline abstract_t">Moriyama B, Henning SA, Childs R, et al. High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients. Ann Pharmacother 2010; 44:929.</a></li><li class="breakAll">IDSA 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections. Infectious Diseases Society of America. Available at: https://www.idsociety.org/practice-guideline/amr-guidance/ (Accessed on June 19, 2023).</li><li><a class="nounderline abstract_t">Walker MC, Lam WM, Manasco KB. Continuous and extended infusions of β-lactam antibiotics in the pediatric population. Ann Pharmacother 2012; 46:1537.</a></li><li><a class="nounderline abstract_t">Rappaz I, Decosterd LA, Bille J, et al. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children. Eur J Pediatr 2000; 159:919.</a></li><li><a class="nounderline abstract_t">Shabaan AE, Nour I, Elsayed Eldegla H, et al. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial. Pediatr Infect Dis J 2017; 36:358.</a></li><li><a class="nounderline abstract_t">Zembles TN, Schortemeyer R, Kuhn EM, et al. Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients. J Pediatr Pharmacol Ther 2021; 26:187.</a></li><li><a class="nounderline abstract_t">Nichols KR, Knoderer CA, Cox EG, Kays MB. System-wide implementation of the use of an extended-infusion piperacillin/tazobactam dosing strategy: feasibility of utilization from a children's hospital perspective. Clin Ther 2012; 34:1459.</a></li><li><a class="nounderline abstract_t">Nichols KR, Karmire LC, Cox EG, et al. Implementing extended-infusion cefepime as standard of care in a children's hospital: a prospective descriptive study. Ann Pharmacother 2015; 49:419.</a></li><li><a class="nounderline abstract_t">Nicasio AM, Quintiliani R Jr, DeRyke CA, et al. Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem. Ann Pharmacother 2007; 41:1077.</a></li><li><a class="nounderline abstract_t">Capitano B, Nicolau DP, Potoski BA, et al. Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections. Pharmacotherapy 2004; 24:803.</a></li><li><a class="nounderline abstract_t">Wrenn RH, Cluck D, Kennedy L, et al. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia. J Oncol Pharm Pract 2018; 24:170.</a></li><li><a class="nounderline abstract_t">Crawford R 3rd, Perkins NB 3rd, Hobbs DA, Hobbs ALV. Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia. Pharmacotherapy 2022; 42:798.</a></li><li><a class="nounderline abstract_t">Cheatham SC, Shea KM, Healy DP, et al. Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients. Int J Antimicrob Agents 2011; 37:46.</a></li><li><a class="nounderline abstract_t">Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother 2010; 54:460.</a></li><li><a class="nounderline abstract_t">Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010; 32:766.</a></li><li><a class="nounderline abstract_t">Thabit AK, Grupper M, Nicolau DP, Kuti JL. Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function. J Pharm Pract 2017; 30:593.</a></li><li><a class="nounderline abstract_t">Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med 2021; 49:e1063.</a></li><li><a class="nounderline abstract_t">Rhodes NJ, MacVane SH, Kuti JL, Scheetz MH. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes. Clin Infect Dis 2014; 59:905.</a></li><li><a class="nounderline abstract_t">Wu CC, Su YC, Wu KS, et al. Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta-analysis and meta-regression analysis. J Clin Pharm Ther 2021; 46:424.</a></li><li><a class="nounderline abstract_t">Grupper M, Kuti JL, Nicolau DP. Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory. Clin Microbiol Rev 2016; 29:759.</a></li><li><a class="nounderline abstract_t">Barlam TF, Cosgrove SE, Abbo LM, et al. Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016; 62:e51.</a></li><li><a class="nounderline abstract_t">Heinrich LS, Tokumaru S, Clark NM, et al. Development and implementation of a piperacillin-tazobactam extended infusion guideline. J Pharm Pract 2011; 24:571.</a></li><li><a class="nounderline abstract_t">Schmees PM, Bergman SJ, Strader BD, et al. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit. Am J Health Syst Pharm 2016; 73:S100.</a></li><li><a class="nounderline abstract_t">Xamplas RC, Itokazu GS, Glowacki RC, et al. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital. Am J Health Syst Pharm 2010; 67:622.</a></li><li><a class="nounderline abstract_t">Brunetti L, Poustchi S, Cunningham D, et al. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center. Ann Pharmacother 2015; 49:754.</a></li></ol></div><div id="topicVersionRevision">Topic 97446 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16945055" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16945055" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24359838" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prolongingβ-lactam infusion: a review of the rationale and evidence, and guidance for implementation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205441" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23571547" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24429437" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : DALI: defining antibiotic levels in intensive care unit patients: are currentβ-lactam antibiotic doses sufficient for critically ill patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27796647" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23074314" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24657044" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Prolonged infusion versus intermittent boluses ofβ-lactam antibiotics for treatment of acute infections: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28760891" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Influence ofβ-Lactam Infusion Strategy on Acute Kidney Injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29020249" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy-What Is the Clinician to Do?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32222460" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute kidney injury following the concurrent administration of antipseudomonalβ-lactams and vancomycin: a network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33735856" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A Comprehensive Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35833959" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Association of vancomycin plus piperacillin-tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35271615" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28079263" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of Rates of Nephrotoxicity Associated with Vancomycin in Combination with Piperacillin-Tazobactam Administered as an Extended versus Standard Infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15620828" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14652981" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19427167" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20411997" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20411997" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20411997" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Length of stay and hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23784164" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26843502" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26843502" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043564" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Stability of meropenem in intravenous solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043564" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Stability of meropenem in intravenous solutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30349291" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30349291" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Training a Drug to Do New Tricks: Insights on Stability of Meropenem Administered as a Continuous Infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9673835" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Community-based parenteral anti-infective therapy (CoPAT). Pharmacokinetic and monitoring issues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23341160" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prolonged infusion antibiotics for suspected gram-negative infections in the ICU: a before-after study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23074313" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23543565" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29608680" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Extended vs Bolus Infusion of Broad-Spectrumβ-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37125229" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical Outcomes With Extended Versus Intermittent Infusion of Anti-Pseudomonal Beta-Lactams in Patients With Gram-Negative Bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29102324" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Prolonged versus short-term intravenous infusion of antipseudomonalβ-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26200166" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A Multicenter Randomized Trial of Continuous versus Intermittentβ-Lactam Infusion in Severe Sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26754759" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33042550" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prolonged versus intermittentβ-lactam antibiotics intravenous infusion strategy in sepsis or septic shock patients: a systematic review with meta-analysis and trial sequential analysis of randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25575030" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21923603" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30649218" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Extended Infusion ofβ-Lactams for Bloodstream Infection in Patients With Liver Cirrhosis: An Observational Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19500529" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21817083" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Rationale and evidence for extended infusion of piperacillin-tazobactam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28486867" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940077" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11939682" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37326473" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With Sepsis: The MERCY Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22742765" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19637794" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : [Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620371" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17867490" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [Clinical efficacy of prolonged (4 hour) drip infusion of meropenem against severe pneumonia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19091523" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449546" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821611" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Standard versus prolonged doripenem infusion for treatment of gram-negative infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24855125" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23750730" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26799442" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Impact of Intraoperative Continuous-Infusion Versus Intermittent Dosing of Cefazolin Therapy on the Incidence of Surgical Site Infections After Coronary Artery Bypass Grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058798" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058798" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33058798" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507068" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507068" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29091209" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32881997" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Modifiable Risk Factors for the Emergence of Ceftolozane-tazobactam Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27012450" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27012450" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ceftolozane/Tazobactam Pharmacokinetics in a Critically Ill Adult Receiving Continuous Renal Replacement Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33618353" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae Infections: A Retrospective Observational Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19258261" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Continuous versus intermittent infusion of oxacillin for treatment of infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397621" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18158083" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19756419" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528265" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Continuous versus intermittent infusions of ceftazidime for treating exacerbation of cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10890260" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371747" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20371747" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115223" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Continuous and extended infusions ofβ-lactam antibiotics in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11131352" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27918382" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33603583" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Extended Infusion of Beta-Lactams Is Associated With Improved Outcomes in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22657253" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : System-wide implementation of the use of an extended-infusion piperacillin/tazobactam dosing strategy: feasibility of utilization from a children's hospital perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614528" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Implementing extended-infusion cefepime as standard of care in a children's hospital: a prospective descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17472997" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Treatment of Serratia marcescens meningitis with prolonged infusion of meropenem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15222672" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Meropenem administered as a prolonged infusion to treat serious gram-negative central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28077047" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36106434" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21074370" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Steady-state pharmacokinetics and pharmacodynamics of cefepime administered by prolonged infusion in hospitalised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19858253" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20435246" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29121839" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34605781" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24867788" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33135261" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Loading dose and efficacy of continuous or extended infusion of beta-lactams compared with intermittent administration in patients with critical illnesses: A subgroup meta-analysis and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27413094" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Continuous and Prolonged Intravenousβ-Lactam Dosing: Implications for the Clinical Laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27080992" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21676847" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Development and implementation of a piperacillin-tazobactam extended infusion guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27208142" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20360589" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25855703" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
